Episode 63
We look at Vosoritide, a promising, potential treatment for children with genetic short stature who do not have chondrodysplasia. Host Aaron Lohr talks with Andrew Dauber, MD, division chief of endocrinology at Children’s National Hospital. Dr. Dauber and colleagues presented about Vosoritide at ENDO 2022. Their abstract is titled, “A Prospective Clinical Trial of Vosoritide in Selected Genetic Causes of Short Stature.”
Stay up to date by copying the following into your podcast player:
https://www.endocrine.org/-/media/endosociety/files/podcasts/enp.xml
Or you can find us on the following streaming services:
Join our endocrine community and become a member! Only members receive access to a variety of member benefits that will enhance your career. If your membership has lapsed, rejoin today so that you can continue to receive your membership benefits.
Our top-ranked peer-reviewed journals are among the first to publish major developments and discovery milestones.
